CAKI-1
CAKI-1 (亦稱ATCC HTB-46) 是人類腎透明細胞癌皮膚轉移細胞系[1]，最初是分離自一名49歲的白人男性腎癌患者[2]。
特徴 编辑
Caki-1細胞中高表達的基因345個，而低表達的基因則有217個[3]。CAKI-1細胞的染色體倍性在三倍體範圍內，並且不存在Y染色體，因為Y染色體的缺失在雄性腫瘤細胞系中並不罕見。除染色體N9和N19以外，所有的染色體都擁有2或3個拷貝。Caki-1細胞有許多微絨毛、發育充分的高爾基體與內質網、細小的線粒體及少許微絲，目前並沒有在細胞內發現任何病毒顆粒。
科研用途 编辑
有學者提議將其作為近端腎小管上皮組織的模型，因為細胞在培養過程中，可以形成具有功能性及高度分化的腎組織形態、生理及生化特徵的極化層 (polarized layer) [4]。有研究指出Caki-1是轉移性腎亮細胞癌的常用模型，當其攜帶着野生型vhl抑癌基因時，它就能在无胸腺裸鼠中產生清晰可見的腫瘤[5]。這些細胞高表達血管內皮生長因子[6]（特別是在氧氣濃度低的情況[7]）的特徵就是腎亮細胞癌的標誌。
參考資料 编辑
- ^ Breuksch, I; Prosinger, F; Baehr, F; Engelhardt, FP; Bauer, HK; Thüroff, JW; Heimes, AS; Hasenburg, A; Prawitt, D; Brenner, W. Integrin α5 triggers the metastatic potential in renal cell carcinoma.. Oncotarget. 2017-12-08, 8 (64): 107530–107542 [2019-12-09]. PMID 29296184. doi:10.18632/oncotarget.22501.
- ^ Fogh, J; Wright, WC; Loveless, JD. Absence of HeLa cell contamination in 169 cell lines derived from human tumors.. Journal of the National Cancer Institute. 1977-02, 58 (2): 209–14 [2019-12-09]. PMID 833871. doi:10.1093/jnci/58.2.209.
- ^ Hehuan Zhu. Bioinformatics analysis of differentially expressed genes in clear cell renal cell carcinoma Caki-1 cell line. Chinese Journal of Cell and Stem Cell. 2018-11, 8 (2): 80–7 [2019-12-09]. doi:10.3877//cma.j.issn.2095-1221.2018.02.003. （原始内容存档于2019-12-09）.
- ^ Glube, N; Giessl, A; Wolfrum, U; Langguth, P. Caki-1 cells represent an in vitro model system for studying the human proximal tubule epithelium.. Nephron. Experimental nephrology. 2007, 107 (2): e47–56 [2019-12-09]. PMID 17804913. doi:10.1159/000107804.
- ^ Lichner, Z; Saleh, C; Subramaniam, V; Seivwright, A; Prud'homme, GJ; Yousef, GM. miR-17 inhibition enhances the formation of kidney cancer spheres with stem cell/ tumor initiating cell properties.. Oncotarget. 2015-03-20, 6 (8): 5567–81 [2019-12-09]. PMID 25011053. doi:10.18632/oncotarget.1901.
- ^ Liu, YH; Lin, CY; Lin, WC; Tang, SW; Lai, MK; Lin, JY. Up-regulation of vascular endothelial growth factor-D expression in clear cell renal cell carcinoma by CD74: a critical role in cancer cell tumorigenesis.. Journal of immunology (Baltimore, Md. : 1950). 2008-11-01, 181 (9): 6584–94 [2019-12-09]. PMID 18941249. doi:10.4049/jimmunol.181.9.6584.
- ^ Miyake, M; Goodison, S; Lawton, A; Zhang, G; Gomes-Giacoia, E; Rosser, CJ. Erythropoietin is a JAK2 and ERK1/2 effector that can promote renal tumor cell proliferation under hypoxic conditions.. Journal of hematology & oncology. 2013-09-03, 6: 65 [2019-12-09]. PMID 24004818. doi:10.1186/1756-8722-6-65.